Meloxicam
DrugOther names: Mobic
NCT Number: NCT02183116
To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days
Looking for future studies?
Notify Me34 year–74 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
none
Other names: Mobic
Time frame: Baseline, 8 weeks after first drug administration
Time frame: Baseline, 8 weeks after first drug administration
Time frame: Baseline, 8 weeks after first drug administration
Time frame: Baseline, 8 weeks after first drug administration
Time frame: Baseline, 8 weeks after first drug administration
Time frame: Baseline, 8 weeks after first drug administration
Time frame: Up to 8 weeks after first drug administration
Time frame: Baseline, 8 weeks after treatment
Boehringer Ingelheim
Industry
Open Study to Access the Efficacy and Safety of Meloxicam 7.5mg in Patients With Osteoarthritis of the Knee
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02108496
Arthritis, Joint Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT07720024
Arthritis, Blount disease
Pathum Thani, Changwat Pathum Thani, Thailand
View Trial DetailsNCT01818401
Arthritis, Joint Diseases
Nantes, France
View Trial DetailsNCT07710404
Arthritis, Joint Diseases
Faisalābad, Punjab Province, Pakistan
View Trial Details